Vibecotamab  (Synonyms: 维克妥单抗; XmAb14045)

Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3^[1][2][3].

half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3

Chimeric

Vibecotamb (Compound XmAb14045) 刺激 T 细胞介导的 CD123⁺ KG-1a 和 TF-1 AML 细胞系杀伤 (EC₅₀ = 8 pM)^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Vibecotamb (Compound XmAb14045) 在小鼠体内的血清半衰期延长至 6.2 天^[3]。
Vibecotamb (0.01-1 mg/kg，单剂量) 在食蟹猴体内给药后 1 小时内即可强烈激活 T 细胞并刺激超过 99% 的循环 CD123⁺ 细胞 (包括嗜碱性粒细胞和浆细胞样树突状细胞) 耗竭^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

126.15 kDa

维克妥单抗; XmAb14045

2138442-13-2

液体

Colorless to light yellow

维克妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3

• 
  Immobilized Vibecotamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC₅₀ for this effect is 0.48 ng/mL.
• 
  Immobilized Vibecotamab can bind Human IL-3R alpha/CD123 Protein (ECD, His Tag). The EC₅₀ for this effect is 7.66 ng/mL.

• [1]. FarhadRavandiMBBS, et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. Blood, Volume 136, Supplement 1, 5 November 2020, Pages 4-5

  [2]. Nicholas James Short et al., Meeting Abstract: 2023 ASCO Annual Meeting I, Journal of Clinical Oncology, Volume 41, Number 16

  [3]. Seung Y. Chu, et al., (2014) Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia, Blood, Volume 124, Issue 21, Page 2316, ISSN 0006-4971.